ZA200804355B - Pharmaceutical compositions comprising buprenorphine - Google Patents
Pharmaceutical compositions comprising buprenorphineInfo
- Publication number
- ZA200804355B ZA200804355B ZA200804355A ZA200804355A ZA200804355B ZA 200804355 B ZA200804355 B ZA 200804355B ZA 200804355 A ZA200804355 A ZA 200804355A ZA 200804355 A ZA200804355 A ZA 200804355A ZA 200804355 B ZA200804355 B ZA 200804355B
- Authority
- ZA
- South Africa
- Prior art keywords
- buprenorphine
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73852405P | 2005-11-21 | 2005-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200804355B true ZA200804355B (en) | 2009-04-29 |
Family
ID=37745944
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200804305A ZA200804305B (en) | 2005-11-21 | 2008-05-19 | Pharmaceutical compositions comprising buprenorphine |
ZA200804355A ZA200804355B (en) | 2005-11-21 | 2008-05-20 | Pharmaceutical compositions comprising buprenorphine |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200804305A ZA200804305B (en) | 2005-11-21 | 2008-05-19 | Pharmaceutical compositions comprising buprenorphine |
Country Status (17)
Country | Link |
---|---|
US (2) | US20070117828A1 (xx) |
EP (2) | EP1951240A2 (xx) |
JP (2) | JP2009516687A (xx) |
KR (1) | KR20080071185A (xx) |
CN (1) | CN101312730A (xx) |
AR (1) | AR058193A1 (xx) |
AU (1) | AU2006316607A1 (xx) |
BR (1) | BRPI0618891A2 (xx) |
CA (2) | CA2630072A1 (xx) |
EC (1) | ECSP088461A (xx) |
NO (1) | NO20082833L (xx) |
NZ (1) | NZ568313A (xx) |
PE (1) | PE20070643A1 (xx) |
RU (1) | RU2008124805A (xx) |
TW (1) | TW200738240A (xx) |
WO (2) | WO2007061739A2 (xx) |
ZA (2) | ZA200804305B (xx) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007112274A2 (en) * | 2006-03-28 | 2007-10-04 | Javelin Pharmaceuticals, Inc. | Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin |
KR20160033796A (ko) | 2006-03-28 | 2016-03-28 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
GB2461681A (en) * | 2008-04-17 | 2010-01-13 | Pharmasol Ltd | Buprenorphine liquid spray formulation with solvent and antioxidant |
PE20081406A1 (es) * | 2006-12-20 | 2008-10-17 | Schering Plough Ltd | Composiciones farmaceuticas de flunixina |
BRPI0818483A2 (pt) * | 2007-11-01 | 2015-04-14 | Bausch & Lomb | Método para preparar uma composição farmacêutica, composição farmacêutica, e, uso da mesma. |
US20110105480A1 (en) * | 2008-06-24 | 2011-05-05 | Keith Freehauf | Pharmaceutical transdermal compositions and method for treating inflammation in cattle |
WO2010072398A2 (en) | 2008-12-22 | 2010-07-01 | Boehringer Ingelheim Limited | Veterinary formulations |
EP2490722A4 (en) * | 2009-10-21 | 2014-03-05 | Otonomy Inc | MODULATION OF THE TEMPERATURE OF GELIFICATION OF FORMULATIONS CONTAINING POLOXAMERS |
GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
MX2013001870A (es) * | 2010-08-17 | 2013-07-03 | Ohr Pharmaceutical Inc | Formulaciones oftalmicas de escualamina. |
WO2012031252A1 (en) * | 2010-09-03 | 2012-03-08 | Abbott Laboratories | High dose buprenorphine compositions and use as analgesic |
CN103298473B (zh) | 2010-10-25 | 2015-07-29 | 曼尼托巴大学 | 用于糖尿病对称性多发神经病变的治疗性组合物 |
US20130115253A1 (en) * | 2011-11-07 | 2013-05-09 | Mahendra R. Patel | Sustained Release Suspension Preparation For Dextromethorphan |
US9468599B2 (en) | 2011-12-27 | 2016-10-18 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
US9962391B2 (en) | 2011-12-27 | 2018-05-08 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
US11213500B2 (en) | 2011-12-27 | 2022-01-04 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
US11213501B2 (en) | 2011-12-27 | 2022-01-04 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
US10813897B2 (en) | 2011-12-27 | 2020-10-27 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
WO2014160702A1 (en) * | 2013-03-25 | 2014-10-02 | Chs Pharma, Inc. | Retinopathy treatment |
EP2983668A4 (en) * | 2013-04-08 | 2017-01-11 | Virginia Commonwealth University | Compositions to alleviate presystemic metabolism of opioids |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
DK3215223T3 (da) | 2014-11-07 | 2020-08-03 | Indivior Uk Ltd | Buprenorphindoseringsskemaer |
JP2018531964A (ja) * | 2015-10-27 | 2018-11-01 | インシス・ディベロップメント・カンパニー・インコーポレイテッド | 液体ブプレノルフィン製剤 |
RS63894B1 (sr) * | 2016-09-13 | 2023-02-28 | Alar Pharmaceuticals Inc | Formulacije buprenorfina sa produženim oslobađanjem |
US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
GB201716830D0 (en) * | 2017-10-13 | 2017-11-29 | Cambrex Charles City Inc | New Process |
JP7378391B2 (ja) | 2017-10-20 | 2023-11-13 | シエシー ファルマセウティチィ ソシエタ ペル アチオニ | 有効成分としてオピオイド受容体アゴニストを含む医薬製剤、その製造方法および治療的使用 |
ES2965836T3 (es) * | 2018-01-22 | 2024-04-17 | Foresee Pharmaceuticals Co Ltd | Composición farmacéutica para administración de liberación mantenida de buprenorfina |
WO2023056043A1 (en) * | 2021-09-30 | 2023-04-06 | Elanco Us Inc. | Stable formulations of buprenorphine |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU8533582A (en) * | 1981-07-10 | 1984-01-12 | Reckitt & Colman Products Limited | Stable solutions of buprenorphine |
US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4931279A (en) * | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
CA2002299A1 (en) * | 1988-11-10 | 1990-05-10 | Eugene G. Drust | Compositions for the transdermal delivery of buprenorphine salts |
US5069909A (en) * | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
US6384043B1 (en) * | 1993-02-01 | 2002-05-07 | Gholam A. Peyman | Methods of alleviating pain sensations of the denuded eye with opioid analgesics |
US5613958A (en) * | 1993-05-12 | 1997-03-25 | Pp Holdings Inc. | Transdermal delivery systems for the modulated administration of drugs |
US5871723A (en) * | 1995-06-06 | 1999-02-16 | The Regent Of The University Of Michigan | CXC chemokines as regulators of angiogenesis |
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
PT889723E (pt) * | 1996-03-25 | 2002-11-29 | Lohmann Therapie Syst Lts | Sistema terapeutico transdermico com pequena espressura da zona de aplicacao e elevada flexibilidade assim como processo de producao |
US6004969A (en) * | 1996-04-15 | 1999-12-21 | National Science Council | Transdermal delivery of buprenorphine preparations |
US5900420A (en) * | 1997-06-19 | 1999-05-04 | Cole; William L. | Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine |
IT1302682B1 (it) * | 1998-10-16 | 2000-09-29 | Formenti Farmaceutici Spa | Composizioni farmaceutiche orali contenenti buprenorfina |
KR100383252B1 (ko) * | 1998-12-17 | 2003-07-16 | 주식회사 삼양사 | 부프레놀핀을함유하는경피투여조성물및이를포함하는패취 |
AU5170400A (en) * | 1999-05-27 | 2000-12-18 | George F. El Khoury | Topical application of muscarinic and opioid agents for treatment of tinnitus |
US6582724B2 (en) * | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
KR100452972B1 (ko) * | 2000-05-16 | 2004-10-14 | 주식회사 삼양사 | 경피투여용 하이드로젤 조성물 |
WO2002005647A1 (en) * | 2000-07-13 | 2002-01-24 | Euro-Celtique, S.A. | Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics |
US20040258740A1 (en) * | 2003-04-10 | 2004-12-23 | Nene Labs | Transdermal delivery composition |
-
2006
- 2006-11-16 US US11/600,560 patent/US20070117828A1/en not_active Abandoned
- 2006-11-16 AU AU2006316607A patent/AU2006316607A1/en not_active Abandoned
- 2006-11-16 JP JP2008541364A patent/JP2009516687A/ja active Pending
- 2006-11-16 AR ARP060105041A patent/AR058193A1/es not_active Application Discontinuation
- 2006-11-16 JP JP2008541335A patent/JP2009516686A/ja not_active Withdrawn
- 2006-11-16 WO PCT/US2006/044464 patent/WO2007061739A2/en active Application Filing
- 2006-11-16 RU RU2008124805/15A patent/RU2008124805A/ru not_active Application Discontinuation
- 2006-11-16 EP EP06837885A patent/EP1951240A2/en not_active Withdrawn
- 2006-11-16 CA CA002630072A patent/CA2630072A1/en not_active Abandoned
- 2006-11-16 EP EP06844380A patent/EP1954275A2/en not_active Withdrawn
- 2006-11-16 US US11/600,418 patent/US20070116730A1/en not_active Abandoned
- 2006-11-16 CN CNA2006800434521A patent/CN101312730A/zh active Pending
- 2006-11-16 WO PCT/US2006/044640 patent/WO2007061828A2/en active Application Filing
- 2006-11-16 BR BRPI0618891-5A patent/BRPI0618891A2/pt not_active IP Right Cessation
- 2006-11-16 CA CA002629560A patent/CA2629560A1/en not_active Abandoned
- 2006-11-16 KR KR1020087014861A patent/KR20080071185A/ko not_active Application Discontinuation
- 2006-11-16 PE PE2006001462A patent/PE20070643A1/es not_active Application Discontinuation
- 2006-11-16 NZ NZ568313A patent/NZ568313A/en not_active IP Right Cessation
- 2006-11-17 TW TW095142635A patent/TW200738240A/zh unknown
-
2008
- 2008-05-19 ZA ZA200804305A patent/ZA200804305B/xx unknown
- 2008-05-19 EC EC2008008461A patent/ECSP088461A/es unknown
- 2008-05-20 ZA ZA200804355A patent/ZA200804355B/xx unknown
- 2008-06-20 NO NO20082833A patent/NO20082833L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NZ568313A (en) | 2011-11-25 |
RU2008124805A (ru) | 2009-12-27 |
AR058193A1 (es) | 2008-01-23 |
KR20080071185A (ko) | 2008-08-01 |
US20070116730A1 (en) | 2007-05-24 |
BRPI0618891A2 (pt) | 2011-09-13 |
NO20082833L (no) | 2008-07-29 |
PE20070643A1 (es) | 2007-08-10 |
CA2629560A1 (en) | 2007-05-31 |
CN101312730A (zh) | 2008-11-26 |
EP1951240A2 (en) | 2008-08-06 |
ZA200804305B (en) | 2009-04-29 |
WO2007061828A3 (en) | 2007-07-19 |
US20070117828A1 (en) | 2007-05-24 |
CA2630072A1 (en) | 2007-05-31 |
JP2009516687A (ja) | 2009-04-23 |
WO2007061739A3 (en) | 2007-07-12 |
EP1954275A2 (en) | 2008-08-13 |
TW200738240A (en) | 2007-10-16 |
WO2007061828A2 (en) | 2007-05-31 |
AU2006316607A1 (en) | 2007-05-31 |
JP2009516686A (ja) | 2009-04-23 |
ECSP088461A (es) | 2008-06-30 |
WO2007061739A2 (en) | 2007-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1244267A1 (zh) | 包含(r)-n-甲基納曲酮的藥物組合物 | |
ZA200804305B (en) | Pharmaceutical compositions comprising buprenorphine | |
IL223545A0 (en) | Pharmaceutical compositions | |
ZA200700030B (en) | Pharmaceutical compositions | |
GB0513692D0 (en) | Novel pharmaceutical compositions | |
GB0408308D0 (en) | Pharmaceutical compositions | |
IL188352A0 (en) | Pharmaceutical compositions | |
EP1871347A4 (en) | PHARMACEUTICAL COMPOSITION | |
PL1837019T3 (pl) | Kompozycja farmaceutyczna rozpadająca się w ustach | |
ZA200804103B (en) | Pharmaceutical compositions | |
EP1805154A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
EP1937255A4 (en) | PHARMACEUTICAL COMPOSITION | |
EP1862184A4 (en) | PHARMACEUTICAL COMPOSITION | |
GB0522045D0 (en) | Pharmaceutical compositions | |
IL192091A0 (en) | Pharmaceutical compositions | |
EP1845944A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
ZA200803566B (en) | Pharmaceutical compositions | |
GB0514259D0 (en) | Pharmaceutical compositions | |
EP1747205A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
GB0502792D0 (en) | Pharmaceutical compositions | |
GB0400971D0 (en) | Pharmaceutical compositions | |
GB0407351D0 (en) | Pharmaceutical compositions | |
GB0411502D0 (en) | Pharmaceutical compositions | |
GB0525269D0 (en) | Pharmaceutical compositions | |
GB0515306D0 (en) | Pharmaceutical compositions |